secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001493152-23-039981
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte Q3 rev $0.4M, op loss $6.5M; VitaGraft Kidney gets CMS coverage
------------------------------------------------------------------------

- Revenue $0.4M; net operating loss $6.5M vs $1.7M in Q3 2022 (which included $6.1M fair value benefit).
- Cash burn reduced to $3.6M; cash, equivalents, and marketable securities $14.2M as of Sep 30, 2023.
- VitaGraft Kidney received positive CMS coverage decision; commercial revenue expected in 1H 2024.
- R&D expense $2.2M (+48% YoY) driven by assay development; SG&A $2.5M (-56% YoY) due to lower stock compensation.
- VitaGraft Liver under review for CMS coverage at MolDX.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223039981/0001493152-23-039981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223039981/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-039981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer